Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications
Research · 2025-01 · 8
DOI: 10.34133/research.0747 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Research, online erschienen am 21.06.2025. Verfasst von Salem Baldi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Diagnostics, School of Medical Technology, Shaoyang University, Shaoyang 422000, China. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 259 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Protein kinases are key mediators of cellular signaling and control cell functions through the phosphorylation of target proteins. They have become major targets for therapeutic agents aimed at treating human diseases, particularly cancer. Protein kinase inhibitors (PKIs) have emerged at the forefront of drug development, and their investigations continue to be intense, with several candidates undergoing clinical trials and persistent endeavors to identify new chemical scaffolds. The main focus is still on developing isoform-selective compounds, which are inhibitors designed to target certain protein kinases, specifically isoforms, for more precise treatment. The identification and advancement of versatile inhibitor scaffolds that more effectively target individual kinases is essential for minimizing off-target effects and resistance. This review highlights important progress in PKI therapy, emphasizing the expansion of treatments for cancer, inflammatory diseases, and neurodegenerative diseases. Future efforts should focus on improving the specificity of inhibitors via mechanistic insights, developing combination therapies, establishing novel strategies, such as CRISPR-Cas9 integration with artificial intelligence-driven drug design, and overcoming resistance to enhance clinical treatment outcomes. Clinical case stories show the challenges and possible opportunities in this quickly evolving area.
Autor:innen und Institutionen
- Department of Medical Laboratory Diagnostics, School of Medical Technology, Shaoyang University, Shaoyang 422000, China.
- Department of Medical Laboratory Diagnostics, Al Thawra General Hospital, Al Hudaydah, Yemen.
- Department of Urology, First Affiliated Hospital, Dalian Medical University, Dalian, China.
- Centre for Biomedical Innovation and Technology, Puai Medical School, Shaoyang University, Shaoyang, China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
ORCID-Profile: Hailin Tang
Zitieren
APA
Baldi, S., Long, N., Ma, S., Liu, L., Al-Danakh, A., Yang, Q., Deng, X., Xie, J., & Tang, H. (2025). Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications. Research, 8. https://doi.org/10.34133/research.0747
Vancouver
Baldi S, Long N, Ma S, Liu L, Al-Danakh A, Yang Q, et al. Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications. Research. 2025;8. doi:10.34133/research.0747
BibTeX
@article{Baldi2025,
author = {Baldi, Salem and Long, Nanbiao and Ma, Shu and Liu, Li and Al-Danakh, Abdullah and Yang, Qin and Deng, Xinpei and Xie, Jindong and Tang, Hailin},
title = {Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications},
journal = {Research},
year = {2025},
volume = {8},
doi = {10.34133/research.0747}
}
EUVIMED